VistaGen’s versatile human pluripotent stem cell (hPSC) technology platform, Human Clinical Trials in a Test Tube™, has been developed to provide clinically relevant predictions of potential toxicity of promising new drug candidates long before they are ever tested in humans. Our hPSC-based bioassay systems more closely approximate human biology than conventional animal testing and other nonclinical techniques and technologies currently used in drug development.

News and Upcoming Events

VistaGen presented at Noble Financial Capital Markets’ 9th Annual Equity Conference. To view CEO Shawn K. Singh’s 25-minute presentation, visit VistaGen Therapeutics Multimedia Webcast.

ImageWith human heart cells derived from hPSCs, we developed CardioSafe 3D™, a novel three-dimensional (3D) bioassay system for predicting in vitro the in vivo cardiac effects of new drug candidates. Our goal is to use CardioSafe 3D™ and modern medicinal chemistry to build a pipeline of novel, safer chemical variants (Drug Rescue Variants™) of once-promising, small molecule drug candidates initially discovered and developed by biotechnology and pharmaceutical companies, the NIH and academic research institutions, but discontinued after substantial investment due to unexpected heart or liver safety concerns.
ImageAV-101, our lead small molecule drug candidate, has successfully completed Phase I development in the U.S. for treatment of neuropathic pain, a serious and chronic condition causing pain after an injury or disease of the peripheral or central nervous system. Neuropathic pain affects millions of people worldwide. We believe our Phase 1 safety program will enable Phase 2 development of AV-101 for neuropathic pain, depression, and potentially other neurological conditions. To date, we have been awarded over $8.8 million from the NIH for development of AV-101.
ImageWith human liver cells derived from hPSCs, we are developing LiverSafe 3D™ as a novel predictive liver toxicology and drug metabolism screening system for drug rescue applications and assessing drug-drug interactions. We are also interested pilot nonclinical studies focused on potential regenerative cell therapy opportunities based on the proprietary hPSC differentiation and cell production capabilities of our Human Clinical Trials in a Test Tube™ platform.